CML is now easily recognized by the presence of the Philadelphia (Ph)-positive chromosomal abnormality and/or the evidence of a specific molecular marker, the disrupted protein kinase BCR/ABL. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.